Trending News

Preparing Covid-19 vaccine for injection
#Immunology / Virology & Vaccines #Pandemic response #University of Queensland #Vaccine candidate #virus

Queensland researchers attempt 150-day vaccine challenge

Queensland researchers are attempting to create a vaccine in just 150 days to prove how far their response capabilities to a viral pandemic have come since Covid-19.  The clock started on 10 February 2025 for The University of Queensland’s Vaccine Rapid Response Team, which has been tasked… Read More

#News #Trending News

Lecanemab
#Alzheimer's #Biogen #Eisai #European Commission #Monoclonal antibodies #Neuroscience

Lecanemab gets EU approval in early Alzheimer’s

The European Commission (EC) has granted Leqembi (lecanemab) Marketing Authorisation (MA) in the European Union (EU).  The approval makes the medicine the first therapy that targets an underlying cause of Alzheimer’s disease (AD) to be granted a MA in the EU.  Lecanemab is indicated for the treatment of adult patients… Read More

#News #Regulatory #Trending News

#Biopharmaceuticals #Generics #Politics #Small molecules #United States

Trump directive aims to cut costs of prescription drugs

US President Trump has signed an executive order designed to lower the cost of prescription drug prices, which includes a win for manufacturers of small molecule drugs.  The order comes one day after the Trump administration instituted a national security report into the pharmaceutical industry, which is likely to be… Read More

#Business & Investment #News #Trending News

Neurons in a brain with Alzheimer's disease
#Alzheimer's #Dementia #Therapeutic Antibodies #UK Dementia Research Institute

Scientists discover why Alzheimer’s drugs are effective

Scientists in the UK and Belgium have discovered new insights into how four different anti-amyloid drugs interact with amyloid beta protein, revealing why the drugs have had varying levels of success at treating Alzheimer’s disease. Amyloid beta is one of the toxic proteins which builds up in clumps… Read More

#News #Trending News

Pfizer, New York
#Clinical trial #GLP-1 #Pfizer #Weight loss

Pfizer discontinues oral GLP-1 receptor agonist danuglipron

Pfizer has announced its decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist, due to drug-induced liver injury.  Danuglipron (PF-06882961) was being investigated for chronic weight management.  The company’s dose-optimisation studies of once-daily formulations of danuglipron met key pharmacokinetic objectives and confirmed a formulation and dose… Read More

#Business & Investment #News #Trending News

Map of Europe
#EFPIA #European Commission #Investment #Pharmaceutical industry #Survey

European pharma CEOs threaten exodus to the US

CEOs of the research-based pharmaceutical industry have issued a stark warning to the European Commission that unless Europe delivers rapid, radical policy change then pharmaceutical research, development and manufacturing is increasingly likely to be directed towards the US.  A survey of European Federation of Pharmaceutical Industries and Associations (EFPIA) member… Read More

#Business & Investment #News #Trending News

#circular RNAs #Phase I trial #RiboX Therapeutics #RNA

First circular RNA begins trials in radiation-induced xerostomia

RiboX Therapeutics has dosed the first patient in its first-in-human (FIH) Phase I/IIa clinical trial (SPRINX-1) evaluating the safety and efficacy of RXRG001 in patients with radiation-induced-xerostomia (RIX) and hyposalivation.  RXRG001 is the first circular RNA therapy to receive FDA IND clearance.  Xerostomia and hyposalivation… Read More

#News #Trending News

Downing Street, London, UK
#Funding #Life sciences #Research and development #UK #UK government

UK government commits £13.9 billion for R&D funding

The UK Department for Science, Innovation and Technology (DSIT) has set out how it will allocate £13.9 ($17.9) billion in funding for transformational research and development in the next year in areas like life sciences, green energy, engineering and beyond.   UK Research and Innovation (UKRI) – the… Read More

#News #Trending News

DNA vector
#Gene editing #Gene therapy #iECURE #Phase II trial

Study indicates gene editing could restore OTC enzyme activity

Gene editing company iECURE has shared data from the ongoing OTC-HOPE Phase I/II study of ECUR-506, which suggest partial restoration of functional ornithine transcarbamylase (OTC) enzyme activity in the first patient dosed.  “Long-term restoration of ornithine transcarbamylase activity has the potential to allow infants afflicted with neonatal… Read More

#News #Trending News

Stand Up for Science, US, March 2025
#Academic #Aix-Marseille Université #Europe #Institut Pasteur #Politics #United States #Vrije Universiteit Brussel

European universities offer scientific refuge to US researchers

Several prestigious European universities are opening their doors to American scientific researchers to provide refuge from what they call “attacks on scientific facts and against researchers”.  The Vrije Universiteit Brussel (VUB) is opening 12 postdoctoral positions for international researchers, which are open to American researchers… Read More

#News #Trending News

#Oncology #Peptides #Transcriptomics #University of Bath

Promising drug candidates for previously ‘undruggable’ target

Reportedly for the first time, researchers from the University of Bath have identified  promising  drug candidates that bind irreversibly with a notoriously ‘undruggable’ cancer protein target, permanently blocking it. Transcription factors are proteins that act as ‘master switches’ of gene activity and play a key role in cancer… Read More

#Cancer Research #News #Trending News

T cells attacking cancer
#Cell therapy #Haematology #Oncology #Orca Bio #Phase III trial

Allogeneic T-cell therapy doubles rate of survival free from GvHD

Biotechnology company Orca Bio has revealed positive results from the Phase III Precision-T study of Orca-T, its lead investigational allogeneic T-cell immunotherapy, in patients with haematological malignancies.  The trial included patients with acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), high-risk myelodysplastic syndrome (MDS) and mixed-phenotype acute… Read More

#Cancer Research #News #Trending News

HIV cell
#Antivirals #Covid-19 #Events #HIV #Immunology / Virology & Vaccines

Breaking virology news from CROI 2025

Several companies shared new trial data at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco, US.  Once-yearly lenacapavir for HIV prevention Gilead Sciences presented the first data from its ongoing Phase I study investigating two once-yearly formulations of lenacapavir, an injectable HIV-1 capsid… Read More

#News #Trending News

Cancer cells
#Japan #Oncology #Phase II trial #Rare cancers

Dual approach could transform treatment of rare cancer

Researchers have combined immunotherapy and chemotherapy to offer new hope for patients with thymic carcinoma, a rare and aggressive cancer.  Thymic carcinoma is often associated with poor prognosis in advanced or recurrent stages. However, its rarity has delayed the development of novel pharmacotherapy.   Now, researchers… Read More

#Cancer Research #News #Trending News

Drugs targeting amyloid Plaque
#Alzheimer's #Drug safety #Eisai #Monoclonal antibodies #National Institute for Health and Care Excellence (NICE)

Researchers call for extra safety monitoring of lecanemab

Researchers from the UK’s Drug Safety Research Unit are calling for the robust monitoring of the safety of lecanemab, a new drug to treat Alzheimer’s disease (AD).  In a review article, published in the British Journal for Clinical Pharmacology, the researchers discuss the need for ongoing assessment of the safety… Read More

#News #Regulatory #Trending News